Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...
Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the ...
Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback